Page 2 - Chief Technical Operations News Today

Sigilon Therapeutics Appoints Sarah Yuan, Ph.D., as Chief Technical Operations Officer Cambridge, MA-February 22, 2022-Sigilon Therapeutics, Inc. , a... | February 22, 2022

Long-term agreement includes a series of investments to acquire new equipment and adapt the present ROVI drug product fill-finish facilities and production lines in SpainCAMBRIDGE, MA and MADRID, SPAIN

Press release content from Accesswire. The AP news staff was not involved in its creation.

16.02.2022 - DGAP-News: Moderna, Inc. / Key word(s): Agreement Moderna and ROVI Expand Long-term Collaboration for the Manufacture of MRNA Medicines Over the Next Ten Years 16.02.2022 / 08:35 The issuer is solely responsible for the content of this ... Seite 1

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Laboratorios Farmacéuticos Rovi, S.A. (BME: ROVI), a pan-European pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules ...

DGAP-News: Moderna, Inc. / Key word(s): Agreement Moderna and ROVI Expand Long-term Collaboration for the Manufacture of MRNA Medicin...

DGAP-News: Moderna, Inc. / Key word(s): Agreement Moderna and ROVI Expand Long-term Collaboration for the Manufacture of MRNA Medicines Over the Next Ten Years 16.02.2022 / 08:35 The issuer is solely responsible for the content of this announcement. MODERNA AND ROVI EXPAND LONG-TERM COLLABORATIO...

CAMBRIDGE, MA / ACCESSWIRE / February 9, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Juan Andres, Chief Technical

Leading RNA intereference (RNAi) therapeutics company, Alnylam, has been welcomed as the latest partner in the Medicines Manufacturing Innovation Centre, to transform the manufacturing process of oligonucleotide therapies. - News - PharmaTimes

/PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), a pharmaceutical company focused on developing novel cancer metabolism therapeutics, today announced the...